[Risk of severe COVID-19 in hypertensive patients treated with renin-angiotensin-aldosterone system inhibitors]

Autor: David Dacal, Héctor Guerrero-Sande, Rafael Golpe, Beatriz Pombo-Vide, Luis A. Pérez-de-Llano, Pablo Ventura-Valcárcel
Rok vydání: 2020
Předmět:
Male
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Lower risk
Article
Angiotensin II type-I receptor blockers
Diabetes Complications
03 medical and health sciences
0302 clinical medicine
Outcome variable
Internal medicine
Diabetes mellitus
Angiotensin-converting enzyme inhibitors
Hipertensión
Renin–angiotensin system
medicine
Humans
030212 general & internal medicine
Aged
Retrospective Studies
business.industry
SARS-CoV-2
Brief Report
Age Factors
Bloqueadores tipo I de angiotensina-II
COVID-19
Retrospective cohort study
General Medicine
medicine.disease
Prognosis
Angiotensin II
Hospitalization
Hypertension
Multivariate Analysis
Female
Inhibidores de la enzima convertidora de angiotensina
business
Cardiomyopathies
Angiotensin II Type 1 Receptor Blockers
Zdroj: Medicina Clinica (English Ed.)
Medicina Clínica
Medicina Clinica
ISSN: 1578-8989
Popis: Introduction There is controversy concerning the use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II type-I receptor blockers (ARB) for treating hypertensive patients with Covid-19. It has been hypothesized that these drugs might increase the risk of severe Covid-19, but some authors suggested that blocking the renin-angiotensin system might actually decrease this risk. Methods Retrospective cohort study of all the consecutive hypertensive patients with confirmed SARS-CoV-2 infection in a health area. The outcome variable was hospitalization because of severe Covid-19. Results 539 subjects were diagnosed of SARS-CoV-2 infection. Of these, 157 (29.1%) had hypertension and were included in the study. Sixty-nine cases (43.9%) were hospitalized because of severe Covid-19. In multivariable analysis older age, diabetes and hypertensive myocadiopathy were related to a higher risk of hospital admission. ARB treatment was associated with a significantly lower risk of hospitalization (HR: 0.29, 95% CI: 0.10 – 0.88). A similar albeit not significant trend was observed for ACEI. Conclusion ARB or ACEI treatment was not associated with a worse clinical outcome in consecutive hypertensive patients infected by SARS-CoV-2.
Databáze: OpenAIRE
Externí odkaz: